Ambeed.cn

首页 / / / / Thalidomide

沙利度胺 /Thalidomide 98%

货号:A164079 同义名: (±)-沙利度胺 / N-Phthaloylglutamimide;K17 Ambeed 开学季,买赠积分,赢豪礼

Thalidomide targets to CRBN with IC50 of 8.5 nM. It can inhibit biosynthesis of TNF-α and has anti-angiogenic and immunosuppressive effects.

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Thalidomide 化学结构 CAS号:50-35-1
Thalidomide 化学结构
CAS号:50-35-1
Thalidomide 3D分子结构
CAS号:50-35-1
Thalidomide 化学结构 CAS号:50-35-1
Thalidomide 3D分子结构 CAS号:50-35-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Thalidomide 纯度/质量文件 产品仅供科研

货号:A164079 标准纯度: 98%
批次查询: 批次纯度:

全球学术期刊中引用的产品

Cell,2024. Ambeed. [ A125712 ]
Cancer Discov., 2024. Ambeed. [ A285925 ]
JMC, 2024, 67(17): 14974-14985. Ambeed. [ A288696 ]
JMC, 2024, 67(17): 15061-15079. Ambeed. [ A524399 , A633512 , A144280 , A174613 ]
EJNMMI Radiopharm. Chem., 2024, 9, 61. Ambeed. [ A1257961 , A622068 ]
更多 >
产品名称 TNF-α 其他靶点 纯度
Thalidomide E3 Ligase 98%
GSK2982772 ++

human RIP1, IC50: 16 nM

99%+
QNZ ++++

TNF-α, IC50: 7 nM

NF-κB 99%+
Lenalidomide +++

TNF-α, IC50: 13 nM

98%
Pomalidomide +++

TNF-α, IC50: 13 nM

98%
GSK481 99%+
Apremilast ++

TNF-α, IC50: 77 nM

98%
Necrostatin-1 +

RIP1, EC50: 490 nM

99%+
N-Ac-Cys-OH 98%
Adalimumab 95%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Thalidomide 生物活性

靶点
  • TNF-α

  • E3 Ligase

描述 Cereblon, encoded by CRBN gene, is the substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Cereblon, or the E3 ligase complex mediated normal degradation of key regulatory proteins is required for multiple biological processes, such as normal limb outgrowth. It is well reported that binding of thalidomide-related drugs, such as Lenalidomide, changes the substrate specificity of the E3 ligase complex, leading to decreased degradation of MEIS2 and other target proteins and increased degradation of MYC, IRF4, IKZF1 and IKZF3{Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X, Ciarlo C, Hartman E, Munshi N, Schenone M, Schreiber SL, Carr SA, Ebert BL. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014 Jan 17;343(6168):301-5. doi: 10.1126/science.1244851. Epub 2013 Nov 29. PMID: 24292625; PMCID: PMC4077049.|https://pubmed.ncbi.nlm.nih.gov/24292625/}}[6]. The cellular target of thalidomide is cereblon. In a fluorescence thermal melt assay utilizing recombinant CRBN (cereblon), it was revealed that thalidomide bound to cereblon[7]. According to a report, thalidomide dose-dependently increased the proliferative responses of PBMCs stimulated by immobilized anti-CD3, with obvious effects shown at the concentration of 10 μg/ml[8]. In a rabbit model of angiogenesis assay, corneal neovascularization was induced by implantation of pellets into corneal micropockets of eyes in anesthetized female New Zealand White rabbits. When given at the dose of 200 mg/kg p.o., thalidomide inhibited the area of vascularized cornea, with a median inhibition of 36%, and the inhibition of thalidomide on angiogenesis was seen after two doses[9]. In a human lung cancer xenograft model established in Balb/c nude mice by subcutaneous injection of PC9 cells, thalidomide was orally administrated at the dose of 200 mg/kg daily for 18 days. In this experiment the combination of thalidomide with icotinib was of significant anti-tumor activity[10].

Thalidomide 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
HeLa cells Function assay Inhibition of IL-1-alpha-induced NF-kappaB activation in HeLa cells assessed as blocking of p50/p65 nuclear translocation, IC50=2.04 μM 17845850
mouse RAW264.7 cells 10 μM Function assay 3 h Reduction in pERK1/2 expression in LPS-activated mouse RAW264.7 cells at 10 uM pretreated for 3 hrs before LPS challenge assessed after 24 hrs by Western blot 18723357
mouse RAW264.7 cells 10 μM Function assay Reduction in iNOS expression in LPS-activated mouse RAW264.7 cells at 10 uM pretreated for 3 hrs before LPS challenge assessed after 24 hrs by Western blot 18723357

Thalidomide 动物研究

Dose Rat: 25 mg/kg - 200 mg/kg[3] (p.o.) Mice: 100 mg/kg[4] (i.p.); 50 mg/kg[4] (p.o.)
Administration p.o.
Pharmacokinetics
Animal Mice[5]
Dose 10 mg/kg (i.v.)
200 mg/kg (p.o.)
Administration i.v.
p.o.
F 100% (i.v.)
240% (p.o.)
AUC0→24h 2.12 μg·h/ml (i.v.)
103 μg·h/ml (p.o.)
T1/2 0.38 h (i.v.)
3.0 h (p.o.)
Tmax 0.083 h (i.v.)
0.5 h (p.o.)
Cmax 5.13 μg/ml (i.v.)
22.17 μg/ml (p.o.)

Thalidomide 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00287872 - Completed - -
NCT00287872 Multiple Myeloma Phase 2 Completed - United States, Maryland ... 展开 >> Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21231-2410 收起 <<
NCT00301405 Chronic Prostatitis ... 展开 >> Pelvic Pain 收起 << Phase 2 Terminated(Study closed. Diffi... 展开 >>cult enrollment of patients with prostatitis.) 收起 << - United States, Michigan ... 展开 >> William Beaumont Hospital Royal Oak, Michigan, United States, 48073 收起 <<

Thalidomide 参考文献

[1]Fischer ES, Bohm K, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014 Aug 7;512(7512):49-53.

[2]D'Amato RJ, Loughnan MS, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5.

[3]Schumacher H, Blake DA, et al. A comparison of the teratogenic activity of thalidomide in rabbits and rats. J Pharmacol Exp Ther. 1968 Mar;160(1):189-200.

[4]Lu J, Palmer BD, et al. Thalidomide metabolites in mice and patients with multiple myeloma. Clin Cancer Res. 2003 May;9(5):1680-8.

[5]Thalidomide

[6]Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG Jr. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014 Jan 17;343(6168):305-9. doi: 10.1126/science.1244917. Epub 2013 Nov 29. PMID: 24292623; PMCID: PMC4070318.

[7]Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF, Chopra R. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012 Nov;26(11):2326-35. doi: 10.1038/leu.2012.119. Epub 2012 May 3. Erratum in: Leukemia. 2012 Nov;26(11):2445. PMID: 22552008; PMCID: PMC3496085.

[8]Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998 Jun 1;187(11):1885-92. doi: 10.1084/jem.187.11.1885. PMID: 9607928; PMCID: PMC2212313.

[9]D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5. doi: 10.1073/pnas.91.9.4082. PMID: 7513432; PMCID: PMC43727.

[10]Sun X, Xu Y, Wang Y, Chen Q, Liu L, Bao Y. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling. Med Sci Monit. 2018 May 15;24:3193-3203. doi: 10.12659/MSM.909977. PMID: 29763936; PMCID: PMC5978026.

Thalidomide 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.87mL

0.77mL

0.39mL

19.36mL

3.87mL

1.94mL

38.73mL

7.75mL

3.87mL

Thalidomide 技术信息

CAS号50-35-1
分子式C13H10N2O4
分子量 258.229
别名 (±)-沙利度胺 ;N-Phthaloylglutamimide;K17;Abbreviation: THAL.;Softenon Talimol;Sedoval K17;Pantosediv;Neurosedyn;Kevadon;Distaval;Thalomid. Foreign brand names: Contergan;Nphthalylglutamic acid imide. US brand names: Synovir;alphaphthalimidoglutarimide. Nphthaloylglutamimide;NSC 527179;NSC 66847;(±)-Thalidomide
运输蓝冰
存储条件

粉末 Keep in dark place,Sealed in dry,Room Temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 105 mg/mL(406.62 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方

IP 2% DMSO+2% Tween80+40% PEG300+water 1.3 mg/mL clear

PO 0.5% CMC-Na 47 mg/mL suspension

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。